Design of an Optimized Scaffold for Affibody Molecules

Journal of Molecular Biology

Volumn 398, Issue 2, 2010, Pages 232-247

  Feldwisch, Joachim ^a,b   Tolmachev, Vladimir ^a,b   Lendel, Christofer ^a   Herne, Nina ^a   Sjöberg, Anna ^a   Larsson, Barbro ^a   Rosik, Daniel ^a   Lindqvist, Eva ^a   Fant, Gunilla ^a   Höidén Guthenberg, Ingmarie ^a   Galli, Joakim ^a   Jonasson, Per ^a   Abrahmsén, Lars ^a  

^a Affibody AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; HER2; Peptide synthesis; Protein engineering; Scaffold

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AFFIBODY; ALANINE; ASPARAGINE; ASPARTIC ACID; BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTAMIC ACID; INSULIN; LEUCINE; MALEIMIDE DERIVATIVE; PHENYLALANINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SERINE; TAQ POLYMERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COOLING; DISSOCIATION CONSTANT; ESCHERICHIA COLI; HEATING; HUMAN; HUMAN CELL; HYDROPHILICITY; MELTING POINT; MOLECULAR MODEL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BINDING; ROOM TEMPERATURE; SURFACE PROPERTY; TEMPERATURE; THERMOSTABILITY; TUMOR XENOGRAFT;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 77951768789     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.03.002     Document Type: Article

References (53)

1. Nilsson B., Moks T., Jansson B., Abrahmsén L., Elmblad A., Holmgren E., et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987, 1:107-113.
2. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 1981, 20:2361-2370.
3. Gouda H., Torigoe H., Saito A., Sato M., Arata Y., Shimada I. Three-dimensional solution structure of the B domain of staphylococcal protein A: comparisons of the solution and crystal structures. Biochemistry 1992, 31:9665-9672.
4. Nord K., Nilsson J., Nilsson B., Uhlén M., Nygren P.Å. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 1995, 8:601-608.
5. Arora P., Oas T.G., Myers J.K. Fast and faster: a designed variant of the B-domain of protein A folds in 3 microsec. Protein Sci. 2004, 13:847-853.
6. Grönwall C., Jonsson A., Lindström S., Gunneriusson E., Ståhl S., Herne N. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 2007, 128:162-183.
7. Wikman M., Steffen A.C., Gunneriusson E., Tolmachev V., Adams G.P., Carlsson J., Ståhl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 2004, 17:455-462.
8. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höidén-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66:4339-4348.
9. Friedman M., Nordberg E., Höidén-Guthenberg I., Brismar H., Adams G.P., Nilsson F.Y., et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel. 2007, 20:189-199.
10. Friedman M., Orlova A., Johansson E., Eriksson T.L., Höidén-Guthenberg I., Tolmachev V., et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J. Mol. Biol. 2008, 376:1388-1402.
11. Kronqvist N., Löfblom J., Jonsson A., Wernerus H., Ståhl S. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng. Des. Sel. 2008, 21:247-255.
12. Jonsson A., Wållberg H., Herne N., Ståhl S., Frejd F.Y. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro. Biotechnol. Appl. Biochem. 2009, 54:93-103.
13. Grönwall C., Ståhl S. Engineered affinity proteins-generation and applications. J. Biotechnol. 2009, 140:254-269.
14. Steffen A.C., Wikman M., Tolmachev V., Adams G.P., Nilsson F.Y., Ståhl S., Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother. Radiopharm. 2005, 20:239-248.
15. Hober S., Nord K., Linhult M. Protein A chromatography for antibody purification. J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2007, 848:40-47.
16. Friedman M., Lindström S., Ekerljung L., Andersson-Svahn H., Carlsson J., Brismar H., et al. Engineering and characterization of a bispecific HER2×EGFR-binding affibody molecule. Biotechnol. Appl. Biochem. 2009, 54:121-131.
17. Rönnmark J., Hansson M., Nguyen T., Uhlén M., Robert A., Ståhl S., Nygren P.Å. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J. Immunol. Methods 2002, 261:199-211.
18. Rönnmark J., Kampf C., Asplund A., Höidén-Guthenberg I., Wester K., Pontén F., et al. Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. J. Immunol. Methods 2003, 281:149-160.
19. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007, 67:2773-2782.
20. Zielinski R., Lyakhov I., Jacobs A., Chertov O., Kramer-Marek G., Francella N., et al. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J. Immunother. 2009, 32:817-825.
21. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr. Pharm. Des. 2008, 14:2999-3019.
22. HER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1008-1018.
23. 18F-labeled protein scaffold molecules. J. Nucl. Med. 2008, 49:804-813.
24. Lundberg E., Höidén-Guthenberg I., Larsson B., Uhlén M., Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J. Immunol. Methods 2007, 319:53-63.
25. Lee S.B., Hassan M., Fisher R., Chertov O., Chernomordik V., Kramer-Marek G., et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin. Cancer Res. 2008, 14:3840-3849.
26. Graille M., Stura E.A., Corper A.L., Sutton B.J., Taussig M.J., Charbonnier J.B., Silverman G.J. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc. Natl Acad. Sci. USA 2000, 97:5399-5404.
27. 2: separation of affinity from specificity. Mol. Immunol. 1993, 30:1279-1285.
28. Jansson B., Uhlén M., Nygren P.Å. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunol. Med. Microbiol. 1998, 20:69-78.
29. Tashiro M., Tejero R., Zimmerman D.E., Celda B., Nilsson B., Montelione G.T. High-resolution solution NMR structure of the Z domain of staphylococcal protein A. J. Mol. Biol. 1997, 272:573-590.
30. Zheng D., Aramini J.M., Montelione G.T. Validation of helical tilt angles in the solution NMR structure of the Z domain of staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data. Protein Sci. 2004, 13:549-554.
31. Lendel C., Dogan J., Härd T. Structural basis for molecular recognition in an affibody:affibody complex. J. Mol. Biol. 2006, 359:1293-1304.
32. Wahlberg E., Lendel C., Helgstrand M., Allard P., Dincbas-Renqvist V., Hedqvist A., et al. An affibody in complex with a target protein: structure and coupled folding. Proc. Natl Acad. Sci. USA 2003, 100:3185-3190.
33. Högbom M., Eklund M., Nygren P.Å., Nordlund P. Structural basis for recognition by an in vitro evolved affibody. Proc. Natl Acad. Sci. USA 2003, 100:3191-3196.
34. Linhult M., Gülich S., Gräslund T., Simon A., Karlsson M., Sjöberg A., et al. Improving the tolerance of a protein A analogue to repeated alkaline exposures using a bypass mutagenesis approach. Proteins 2004, 55:407-416.
35. Sasso E.H., Silverman G.J., Mannik M. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J. Immunol. 1991, 147:1877-1883.
36. Ruczynski J., Lewandowska B., Mucha P., Rekowski P. Problem of aspartimide formation in Fmoc-based solid-phase peptide synthesis using Dmab group to protect side chain of aspartic acid. J. Pept. Sci. 2008, 14:335-341.
37. Taverna D.M., Goldstein R.A. Why are proteins so robust to site mutations?. J. Mol. Biol. 2002, 315:479-484.
38. He Y., Chen Y., Alexander P., Bryan P.N., Orban J. NMR structures of two designed proteins with high sequence identity but different fold and function. Proc. Natl Acad. Sci. USA 2008, 105:14412-14417.
39. Decristoforo C., Mather S.J. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl. Med. Biol. 1999, 26:389-396.
40. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25:1165-1170.
41. Lendel C., Dincbas-Renqvist V., Flores A., Wahlberg E., Dogan J., Nygren P.Å., Härd T. Biophysical characterization of Z(SPA-1)-a phage-display selected binder to protein A. Protein Sci. 2004, 13:2078-2088.
42. Lacroix E., Viguera A.R., Serrano L. Elucidating the folding problem of alpha-helices: local motifs, long-range electrostatics, ionic-strength dependence and prediction of NMR parameters. J. Mol. Biol. 1998, 284:173-191.
43. Bai Y., Karimi A., Dyson H.J., Wright P.E. Absence of a stable intermediate on the folding pathway of protein A. Protein Sci. 1997, 6:1449-1457.
44. Alonso D.O., Daggett V. Staphylococcal protein A: unfolding pathways, unfolded states, and differences between the B and E domains. Proc. Natl Acad. Sci. USA 2000, 97:133-138.
45. Ghosh A., Elber R., Scheraga H.A. An atomically detailed study of the folding pathways of protein A with the stochastic difference equation. Proc. Natl Acad. Sci. USA 2002, 99:10394-10398.
46. Quibell M., Johnson T. Difficult peptides. Fmoc Solid Phase Peptide Synthesis-A Practical Approach 2000, 115-135. Oxford University Press, Oxford. W.C. Chan, P.D. White (Eds.).
47. Haack T., Mutter M. Serine derived oxazolidines as secondary structure disrupting, solubilizing building blocks in peptide synthesis. Tetrahedron Lett. 1992, 33:1589-1592.
48. Engfeldt T., Renberg B., Brumer H., Nygren P.Å., Karlström A.E. Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 2005, 6:1043-1050.
49. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., Sandström M., et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007, 67:2178-2186.
50. Studier F.W., Rosenberg A.H., Dunn J.J., Dubendorff J.W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 1990, 185:60-89.
51. Ahlgren S., Orlova A., Rosik D., Sandström M., Sjöberg A., Baastrup B., et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug. Chem. 2008, 19:235-243.
52. Koradi, R., Billeter, M. & Wüthrich, K. (1996). MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics, 14, 51-55., 29-32.
53. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2723.